Amino Chemicals Ltd

Divi’s Laboratories Limited (Divi’s), is a pharmaceutical company headquartered in Hyderabad, India.
Divi’s is engaged in manufacturing leading generic compounds, nutraceutical ingredients and custom synthesis of APIs and intermediates for global innovator companies primarily for export to regulated markets such as US and Europe. With two manufacturing facilities, market presence across several countries and a team of 10,000 employees, Divi’s continues to innovate to bring robust techniques to facilitating sustainable manufacturing processes.

The company was founded in 1990 by Dr. Murali K Divi with research and development as its core area. Started initially as a Research and Development Center, it expanded and focused on developing new processes for the production of Active Pharma Ingredients (APIs) & Intermediates, providing complete turnkey solutions and consulting to the domestic pharmaceutical industry.

Mainly supplying the international API market, ScinoPharm has become one of the leading international oncology generic APIs suppliers (in terms of generic APIs supply). In addition to anti-cancer APIs, we have also developed a wide variety of other products including CNS APIs, gastrointestinal APIs, etc.

Symphony was founded by eminent experts from Pharma Industry to create new bench mark in collaborative Research and Services.

Symphony provides Chemistry Services for:

 Chemistry support for early stage drug discovery molecules, building blocks & scaffolds, analogues & library compounds synthesis
 cGMP Kilo scale manufacturing & supply (up to 25Kg) of clinical drug substance (NCE) for preclinical to clinical studies
 CMC documentation & support for NDA submission
 Experience of working on more than 40 NCEs for our Global Innovator clients on FTE (Full Time Equivalent) & FFS (Fee For Service) client engagement models.
 Custom Synthesis from mg to kg for non-catalogue/expensive catalogue compounds
 Non-infringing and cost effective process development for generic APIs and intermediates and technical package submissions for commercial manufacturing
 Process validations under cGMP pilot plant
 Analytical (HPLC/GC) method development & validations


Symphony has expert team of Scientists and marketing professionals with an excellent track record of Research and timely delivery capabilities.

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated contract research, development and manufacturing organization providing scientific services – from early discovery to commercial supply. Our innovative capabilities for novel molecular entities (NMEs) cater to a wide range of industrial sectors, including pharmaceutical, biotechnology, nutrition, animal health, consumer goods and speciality chemical companies.

Our Discovery services include conducting early-stage research from target identification to delivery of drug candidates for further development. Development services encompass activities from pre-clinical to clinical trials including Drug Substance Development (DSP), Drug Product Development (DPD) and associated services to demonstrate safety, tolerability and efficacy of the selected drug candidate.

Our Manufacturing services for small and large molecules include cGMP-compliant facilities for clinical supplies, registration batches as well as commercial volumes through our API manufacturing plant & disposable Biologics manufacturing facility.

Driving our innovative culture is our highly qualified team of 4200 scientists supported by state-of-the-art infrastructure and market-leading technology. Our scientists have both the skills and the capability to deliver great science, ensure robust data management, IP security & quality manufacturing, at speed, to improve time-to-market and lower the cost of innovation.

With 2 Mn sq ft of specialist discovery, development & manufacturing facilities, Syngene offers dedicated research facilities for Amgen, Baxter, Bristol-Myers Squibb and Herbalife. We also work with biotech companies pursuing leading-edge science as well as multinationals including GSK and Merck KGaA. Smaller and virtual companies, non-profit institutions, academic centers and start-ups also collaborate with us for their research-related requirements.

Write to us at bdc@syngeneintl.com

The ACIC Group, founded in 1973 by Luciano Calenti, is a full-service pharmaceutical company. The company started in API and has a long successful array of projects satisfying customers and partners in the API business in the Generic and Brand Name Pharmaceutical field.

Our strength is our joint ventures with our API manufacturing partners, as well as finished dosage form clients. All our plants are FDA inspected and meet cGMP. Our strength is to help in joint venture deals in financing companies, and financing projects as true partners in the global business.

ACIC has been very active with Injectables in the last 12 years, obtaining multiple ANDA’s. ACIC built and upgraded facilities up to GMP standards in many countries. One of which is Canlac, located in Quebec. Canlac is the worlds largest lactulose Plant, now an Abbott Plant. ACIC tirelessly worked for a couple of decades with a new compound which is sold globally by a leading pharmaceutical company.

ACIC Pharmaceutical Machinery was also founded, specializing in equipment for injection production, and becoming the leader in radioactive injectable production as well as in Artificial Intelligence inspection equipment for injectable products.

We truly reflect our tag line, “from Molecule to Market"